Clinical Trial Update: Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients [Phase 2]

View source ↗

Summary

Phase II trial evaluating pirtobrutinib in combination with rituximab for previously untreated low- and intermediate-risk mantle cell lymphoma; currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Pirtobrutinib (LOXO-305) (pirtobrutinib)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING